Role of toll-like receptors in multiple myeloma and recent advances

Experimental Hematology

Volumn 43, Issue 3, 2015, Pages 158-167

  Thakur, Krishan K ^a   Bolshette, Nityanand B ^a   Trandafir, Cristiana ^b   Jamdade, Vinayak S ^a   Istrate, Alexandru ^b   Gogoi, Ranadeep ^a   Cucuianu, Andrei ^c  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; AS 04; AS 15; BCG VACCINE; BORTEZOMIB; C 792; COMPOUND 852A; CORTICOSTEROID; CYTOTOXIC AGENT; GNKG 168; HILTONOL; IMIQUIMOD; IMM 101; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMO 2055; IMO 8400; INTERFERON; MELPHALAN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG TOLERABILITY; GLIOMA; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INNATE IMMUNITY; KIDNEY CARCINOMA; MELANOMA; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY; WALDENSTROEM MACROGLOBULINEMIA; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; TRENDS;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84924960274     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.11.003     Document Type: Review

References (103)

1. Nieters A., Beckmann L., Deeg E., Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006, 7:615-624.
2. Abdi J., Mutis T., Garssen J., Redegeld F. Characterization of the Toll-like receptor expression profile in human multiple myeloma cells. PLoS One 2013, 8:e60671.
3. Bao H., Lu P., Li Y., et al. Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol Ther 2011, 11:58-67.
4. Jego G., Bataille R., Geffroy-Luseau A., Descamps G., Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006, 20:1130-1137.
5. Xu Y., Zhao Y., Huang H., et al. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol 2010, 150:543-553.
6. Liu J., Hamrouni A., Wolowiec D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
7. Abdi J., Mutis T., Garssen J., Redegeld F. Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells. Blood Cancer J 2013, 3:e119.
8. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
9. Dorner M., Brandt S., Tinguely M., et al. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009, 128:573-579.
10. Ellyard J.I., Simson L., Parish C.R. Th2-mediated anti-tumour immunity: friend or foe?. Tissue Antigens 2007, 70:1-11.
11. Wyllie D.H., Kiss-Toth E., Visintin A., et al. Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses. JImmunol 2000, 165:7125-7132.
12. Ramaiah S.K., Gunthner R., Lech M., Anders H.J. Toll-like receptor and accessory molecule mRNA expression in humans and mice as well as in murine autoimmunity, transient inflammation, and progressive fibrosis. Int J Mol Sci 2013, 14:13213-13230.
13. Butt A.Q., Mills K.H. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2014, 33:4623-4631.
14. Ghanim H., Mohanty P., Deopurkar R., et al. Acute modulation of toll-like receptors by insulin. Diabetes Care 2008, 31:1827-1831.
15. Grueber C.E., Wallis G.P., King T.M., Jamieson I.G. Variation at innate immunity Toll-like receptor genes in a bottlenecked population of a New Zealand robin. PLoS One 2012, 7:e45011.
16. So E.Y., Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci 2010, 6:675-681.
17. Sweet M.J., Leung B.P., Kang D., et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001, 166:6633-6639.
18. Spaner D.E., Foley R., Galipeau J., Bramson J. Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene 2008, 27:208-217.
19. Chiron D., Pellat-Deceunynck C., Amiot M., Bataille R., Jego G. TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol 2009, 182:4471-4478.
20. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002, 23:375-378.
21. Hashimoto C., Hudson K.L., Anderson K.V. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988, 52:269-279.
22. Avbelj M., Horvat S., Jerala R. The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition of TLRs. J Immunol 2011, 187:2394-2404.
23. Carty M., Bowie A.G. Recent insights into the role of Toll-like receptors in viral infection. Clin Exp Immunol 2010, 161:397-406.
24. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
25. Janssens S., Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003, 16:637-646.
26. Onnis A., Navari M., Antonicelli G., et al. Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma. Blood Cancer J 2012, 2:e84.
27. Chiron D., Bekeredjian-Ding I., Pellat-Deceunynck C., Bataille R., Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 2008, 112:2205-2213.
28. Shcheblyakov D.V., Logunov D.Y., Tukhvatulin A.I., Shmarov M.M., Naroditsky B.S., Gintsburg A.L. Toll-Like Receptors (TLRs): The Role in Tumor Progression. Acta Naturae 2010, 2:21-29.
29. Godfroy J.I., Roostan M., Moroz Y.S., Korendovych I.V., Yin H. Isolated Toll-like receptor transmembrane domains are capable of oligomerization. PLoS One 2012, 7:e48875.
30. Abdi J., Mutis T., Garssen J., Redegeld F.A. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis. PLoS One 2014, 9:e96608.
31. Matsumoto M., Funami K., Tanabe M., et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003, 171:3154-3162.
32. Chiron D., Jego G., Pellat-Deuceunynck C. Toll-like receptors: expression and involvement in multiple myeloma. Leuk Res 2010, 34:1545-1550.
33. Reynolds J.M., Martinez G.J., Chung Y., Dong C. Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci U S A 2012, 109:13064-13069.
34. Hayashi F., Smith K.D., Ozinsky A., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
35. Chamberlain N.D., Vila O.M., Volin M.V., et al. TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-alpha levels. JImmunol 2012, 189:475-483.
36. Cho H.Y., Lee S.W. TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells. Cell Immunol 2014, 289:27-35.
37. Lehmann S.M., Kruger C., Park B., et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 2012, 15:827-835.
38. Li Z.J., Sohn K.C., Choi D.K., et al. Roles of TLR7 in activation of NF-kappaB signaling of keratinocytes by imiquimod. PLoS One 2013, 8:e77159.
39. Tang S.C., Yeh S.J., Li Y.I., et al. Evidence for a detrimental role of TLR8 in ischemic stroke. Exp Neurol 2013, 250:341-347.
40. Onji M., Kanno A., Saitoh S., et al. An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing. Nat Commun 2013, 4:1949.
41. Koulis C., Chen Y.C., Hausding C., et al. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2014, 34:516-525.
42. Mulla M.J., Myrtolli K., Tadesse S., et al. Cutting-edge report: TLR10 plays a role in mediating bacterial peptidoglycan-induced trophoblast apoptosis. Am J Reprod Immunol 2013, 69:449-453.
43. Lee S.M., Kok K.H., Jaume M., et al. Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci U S A 2014, 111:3793-3798.
44. Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol 2014, 14:109-121.
45. Hoebe K., Du X., Georgel P., et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003, 424:743-748.
46. Valkovic T., Nacinovic A.D., Petranovic D. Prophylactic broad spectrum antibiotics as a new anti-myeloma therapy. Med Hypotheses 2013, 81:1137-1140.
47. Augustson B.M., Begum G., Dunn J.A., et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005, 23:9219-9226.
48. Blimark C, Mellqvist UH, Landgren O, et al. Multiple myeloma andinfections: A population-based study based on 9,610 multiple myeloma patients. 2012 ASH Annual Meeting. Abstract 945. Presented December 11, 2012.
49. Teng H.W., Teng C.J., Wang W.S., et al. High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen. Am J Hematol 2010, 85:812-815.
50. Karlsson J., Hogevik H., Andersson K., Roshani L., Andréasson B., Wennerås C. Pneumococcal vaccine responses in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Trials Vaccinol 2013, 2:31-38.
51. Cole J.E., Mitra A.T., Monaco C. Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets. Expert Rev Cardiovasc Ther 2010, 8:1619-1635.
52. Hornung V., Rothenfusser S., Britsch S., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
53. Romieu-Mourez R., Francois M., Boivin M.N., Bouchentouf M., Spaner D.E., Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009, 182:7963-7973.
54. Manier S., Sacco A., Leleu X., Ghobrial I.M., Roccaro A.M. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012, 2012:157496.
55. Bohnhorst J., Rasmussen T., Moen S.H., et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006, 20:1138-1144.
56. Hajishengallis G. Toll gates to periodontal host modulation and vaccine therapy. Periodontol 2000 2009, 51:181-207.
57. Tinhofer I., Marschitz I., Henn T., Egle A., Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000, 95:610-618.
58. Park S.H., Cho G., Park S.G. NF-kappaB Activation in T Helper 17 Cell Differentiation. Immune Netw 2014, 14:14-20.
59. Frassanito M.A., Cusmai A., Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 2001, 125:190-197.
60. Spaner D.E., Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007, 21:53-60.
61. Yamamoto M., Sato S., Hemmi H., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301:640-643.
62. Abdi J., Engels F., Garssen J., Redegeld F. The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. Crit Rev Oncol Hematol 2011, 80:225-240.
63. Danylesko I., Beider K., Shimoni A., Nagler A. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol 2012, 2012:753407.
64. Norgaard N.N., Holien T., Jonsson S., et al. CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and invitro osteoblastogenesis. JImmunol 2010, 185:3131-3139.
65. Kawai T., Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007, 13:460-469.
66. Salaun B., Romero P., Lebecque S. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 2007, 37:3311-3318.
67. Calame K. Activation-dependent induction of Blimp-1. Curr Opin Immunol 2008, 20:259-264.
68. Shapiro-Shelef M., Lin K.I., Savitsky D., Liao J., Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 2005, 202:1471-1476.
69. Hope C., Ollar S.J., Heninger E., et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood 2014, 123:3305-3315.
70. Ghosh N., Matsui W. Cancer stem cells in multiple myeloma. Cancer Lett 2009, 277:1-7.
71. Hawley T.S., Riz I., Yang W., et al. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol 2013, 88:265-272.
72. Staudinger M., Glorius P., Burger R., et al. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells. Blood Cancer J 2014, 4:e219.
73. Mogensen T.H., Berg R.S., Paludan S.R., Ostergaard L. Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae. Infect Immun 2008, 76:189-197.
74. Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med 2012, 18:1332-1334.
75. Lonial S., Mitsiades C.S., Richardson P.G. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011, 17:1264-1277.
76. Ray A., Tian Z., Das D.S., et al. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia 2014, 28:1716-1724.
77. Allegra A., Penna G., Alonci A., et al. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol 2013, 90:441-468.
78. Huang B., Zhao J., Unkeless J.C., Feng Z.H., Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
79. Shotorbani S.S., Su Z.L., Xu H.X. Toll-like receptors are potential therapeutic targets in rheumatoid arthritis. World J Biol Chem 2011, 2:167-172.
80. Ferrari-Lacraz S., Burger D. RANKing bone resorption versus inflammation: Infection makes the decision. IBMS BoneKEy 2010, 7:156-160.
81. Lundberg A.M., Ketelhuth D.F., Johansson M.E., et al. Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc Res 2013, 99:364-373.
82. O'Neill L.A., Bryant C.E., Doyle S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009, 61:177-197.
83. Makkouk A., Abdelnoor A.M. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol Immunotoxicol 2009, 31:331-338.
84. Weigel B.J., Cooley S., DeFor T., et al. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol 2012, 87:953-956.
85. Zhang Q., Hossain D.M., Nechaev S., et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells invivo. Blood 2013, 121:1304-1315.
86. Delgado M.A., Elmaoued R.A., Davis A.S., Kyei G., Deretic V. Toll-like receptors control autophagy. EMBO J 2008, 27:1110-1121.
87. Takeda K., Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17:1-14.
88. Hideshima T., Bergsagel P.L., Kuehl W.M., Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104:607-618.
89. Cherfils-Vicini J., Platonova S., Gillard M., et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010, 120:1285-1297.
90. Goto Y., Arigami T., Kitago M., et al. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 2008, 7:3642-3653.
91. Guo H., Chen Y., Hu X., Qian G., Ge S., Zhang J. The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells. Mol Cancer 2013, 12:77.
92. Wolska A., Lech-Maranda E., Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009, 14:248-272.
93. Chen H., Li M., Campbell R.A., Burkhardt K., Zhu D. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene 2006, 25:6520-6527.
94. Steinhagen F., Kinjo T., Bode C., Klinman D.M. TLR-based immune adjuvants. Vaccine 2011, 29:3341-3355.
95. Parkinson T. The future of toll-like receptor therapeutics. Curr Opin Mol Ther 2008, 10:21-31.
96. Vacchelli E., Eggermont A., Sautès-Fridman C., et al. Toll-like receptor agonists for cancer therapy. OncoImmunology 2013, 2:e25238.
97. Gosu V., Basith S., Kwon O.P., Choi S. Therapeutic applications of nucleic acids and their analogues in toll-like receptor signaling. Molecules 2012, 17:13503-13529.
98. Stebbing J., Dalgleish A., Gifford-Moore A., et al. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann Oncol 2012, 23:1314-1319.
99. Didierlaurent A.M., Morel S., Lockman L., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
100. De Gregorio E., Caproni E., Ulmer J.B. Vaccine adjuvants: mode of action. Front Immunol 2013, 4:214.
101. Suárez-Fariñas M., Arbeit R., Jiang W., et al. Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS One 2013, 8:e84634.
102. Smith D.A., Conkling P., Richards D.A., Nemunaitis J.J., Boyd T.E. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunol Immunother 2014, 63:787-796.
103. Belani C.P., Nemunaitis J.J., Chachoua A., et al. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther 2013, 14:557-563.